相关实验视频
Updated: Jan 12, 2026

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
10.0K
突变的p53结合并控制雌激素受体活性,以驱动卵巢癌中的内分泌抵抗
Chunlei Shao1, Alexandra Indeglia1, Maya Foster1,2
1Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Genes & development
|November 5, 2025
概括
突变p53阻碍卵巢癌中的雌激素受体α (ERα),导致内分泌疗法耐药性. 沉默突变p53恢复ERα功能,改善高度血清性卵巢癌 (HGSOC) 的治疗灵敏度.
科学领域:
- 妇科瘤学 妇科瘤学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 高度血清性卵巢癌 (HGSOC) 的死亡率很高,在化疗后经常复发.
- 雌激素受体α (ERα) 存在于~70%的HGSOC瘤中,这表明内分泌治疗的潜力.
- 目前用于HGSOC的内分泌疗法有效性有限,这表明需要新的治疗策略.
研究的目的:
- 调查突变p53在ERα功能中的作用和HGSOC中的内分泌治疗耐药性.
- 探索突变p53影响ERα信号传递的机制.
- 评估向突变p53或恢复ERα活性的治疗潜力.
主要方法:
- 在HGSOC细胞中对ERα结合的突变p53的分析.
- 评估ERα-SP1基因在突变p53.3存在或不存在时的交换活化.
- 在突变p53沉默后对内分泌治疗的HGSOC敏感性的评估.
- 测试p53突变Y220C重新折叠化合物 (rezatapopt) 与富尔韦斯特兰特结合的疗效.
主要成果:
- 误解突变p53直接结合并抑制HGSOC中的ERα活性.
- 突变的p53赋予了对内分泌疗法的耐药性,如富尔韦斯特兰特和埃拉塞斯特兰特.
- 突变p53特别阻断ERα-SP1目标基因的交换活化,包括DEPTOR,一个mTOR调节器.
- 沉默突变p53恢复ERα功能并使HGSOC对内分泌治疗敏感.
- 雷扎塔波普特在Y220C突变细胞系中增强了富尔韦斯特兰特的反应.
结论:
- 突变p53是通过抑制ERα在HGSOC中的内分泌治疗耐药性的关键驱动因素.
- 向突变的p53或恢复ERα信号传输为HGSOC提供了一个有希望的治疗途径.
- 涉及内分泌疗法和突变p53调节器的组合策略需要进一步的临床研究.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Hormonal Control of the Ovarian Cycle
6.4K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
6.4K
Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K

